跳至主要内容
临床试验/NCT01600079
NCT01600079已完成不适用

Post-Licensure Observational Study of the Long-term Effectiveness of ZOSTAVAX™

Merck Sharp & Dohme LLC0 个研究点目标入组 1,505,647 人开始时间: 2012年5月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,505,647
主要终点
Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts by Time since Vaccination

研究概览

简要总结

This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants with continuous Kaiser Permanente Northern California (KPNC) membership since becoming age-eligible for ZOSTAVAX™ and with 12 months of continuous enrollment in KPNC before their study start date

排除标准

  • 未提供

结局指标

主要结局

Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts by Time since Vaccination

时间窗: 10 years

Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts, Overall, and by Age (50-59, 60-69, 70-79 ≥80) at Vaccination

时间窗: 10 years

次要结局

  • Incidence of Postherpetic Neuralgia in Vaccinated and Unvaccinated Cohorts, Overall, and by Age (50-59, 60-69, 70-79, ≥80) at Vaccination(10 years)
  • Incidence of Postherpetic Neuralgia in Vaccinated and Unvaccinated Cohorts by Time since Vaccination(10 years)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验